| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
microtubule
Verubulin hydrochloride targets tubulin, inhibiting tubulin polymerization. As a microtubule destabilizer and vascular disrupting agent (VDA), it disrupts the microtubule network, leading to cell cycle arrest and apoptosis in cancer cells. |
|---|---|
| ln Vitro |
Verubulin hydrochloride is the hydrochloride of compound Verubulin. With GI50 values of 3–6 nM in T47D, HCT116, and SNU-398 cells, verubulin (MPC-6827) is a strong inhibitor of cancer cell growth.[2]
In vitro, Verubulin hydrochloride inhibits tubulin polymerization in a cell-free assay at concentrations of 0.5, 5, and 50 μM. It is a potent inhibitor of cancer cell growth, with GI50 values of 3-6 nM in T47D, HCT116, and SNU-398 cells. |
| ln Vivo |
Verubulin (MPC-6827) is effective in an MX-1 breast tumor model and has good blood-brain barrier penetration.[2]
In vivo, Verubulin hydrochloride exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. It achieves high brain concentration relative to plasma in animals, making it a promising candidate for the treatment of brain tumors. |
| Enzyme Assay |
The in vitro tubulin polymerization assay involves incubating purified tubulin with varying concentrations of Verubulin hydrochloride and measuring the extent of polymerization by spectrophotometry. The inhibition of polymerization is calculated from the dose-response curve.
|
| Cell Assay |
In vitro cell-based assays for Verubulin hydrochloride utilize cancer cell lines such as T47D, HCT116, and SNU-398. Cells are treated with the compound, and cell viability is assessed by MTT or CellTiter-Glo assays. Cell cycle analysis and apoptosis detection are performed by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for Verubulin hydrochloride are performed in xenograft models using human MX-1 breast cancer cells or other cancer cell lines. The compound is administered, and tumor growth is monitored.
|
| ADME/Pharmacokinetics |
Verubulin hydrochloride has a molecular weight of 315.80 g/mol and is soluble in DMSO. It is typically stored as a powder at -20°C. Its purity is ≥98%.
|
| Toxicity/Toxicokinetics |
Toxicological data for Verubulin hydrochloride are limited, as it is a research compound. As a microtubule-destabilizing agent, it has potential for significant biological effects. It is not intended for human use. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Verubulin hydrochloride is the hydrochloride form of Verubulin, a quinazoline derivative with potential dual antitumor activity. Verubulin binds to tubulin and inhibits its polymerization, thereby blocking microtubule formation, leading to disordered spindle assembly during mitosis, cell cycle arrest at the G2/M phase, and ultimately cell death. This drug is not a substrate for many multidrug resistance ABC transporter subtypes (such as P-glycoprotein, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1)); therefore, it may be effective against multidrug-resistant (MDR) tumors expressing these transporters. Furthermore, as a vascular disruptor (VDA), Verubulin appears to specifically disrupt tumor microvessels, potentially leading to acute ischemia and massive tumor cell death.
Verubulin hydrochloride is a research compound with no clinical approval. It is a promising candidate for the treatment of multiple cancer types, particularly brain tumors, due to its BBB penetration. It is used in drug discovery programs to explore the therapeutic potential of microtubule-destabilizing agents and vascular disrupting agents. |
| Molecular Formula |
C₁₇H₁₈CLN₃O
|
|---|---|
| Molecular Weight |
315.80
|
| Exact Mass |
315.114
|
| Elemental Analysis |
C, 64.66; H, 5.75; Cl, 11.23; N, 13.31; O, 5.07
|
| CAS # |
917369-31-4
|
| Related CAS # |
Verubulin;827031-83-4
|
| PubChem CID |
11638255
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.516
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
330
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.N1C2C(=CC=CC=2)C(N(C)C2C=CC(OC)=CC=2)=NC=1C
|
| InChi Key |
VYUWDIKZJLOZJL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H17N3O.ClH/c1-12-18-16-7-5-4-6-15(16)17(19-12)20(2)13-8-10-14(21-3)11-9-13;/h4-11H,1-3H3;1H
|
| Chemical Name |
N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine;hydrochloride
|
| Synonyms |
MPC-6827; MPC6827; MPC 6827; Verubulin HCl; Verubulin hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO 56~62.5 mg/mL (177.3~197.9 mM)
Ethanol: ~56 mg/mL (~177.3 mM) Water: ~56 mg/mL (~177.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1666 mL | 15.8328 mL | 31.6656 mL | |
| 5 mM | 0.6333 mL | 3.1666 mL | 6.3331 mL | |
| 10 mM | 0.3167 mL | 1.5833 mL | 3.1666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
